Developer docs
API playgroundTry for free, no card

Search company profiles

Verisfield

Full company profile

uuid003a7qh

Namestring
Verisfield
Websiteurl
verisfield.gr
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Verisfield is a Greek pharmaceutical company that specialises in the development and marketing of generic pharmaceutical products. Founded in 2000 and headquartered in Athína (Athens), the company operates as a for-profit private entity with a headcount of 51–100 employees. Its business model is anchored in the generics segment, where value is created by developing, registering, and commercialising off-patent pharmaceutical products for therapeutic substitution at lower price points than originator brands.

The input source material returned a loading/verification page rather than substantive company content, and most standard data fields — revenue, leadership, product list, partnerships, funding, technology stack, geographic footprint, certifications, and customer base — are not populated. As a result, the technical architecture, specific product portfolio, regulatory authorisations, distribution channels, and end-customer segments are not documented. Operating geography is limited to a single disclosed location (Athens), and the website domain (verisfield.gr) suggests a primary Greek market orientation, though export activity cannot be confirmed from the available data.

Revenue mechanics, pricing model, and go-to-market motion are not disclosed. In the absence of named customers, distribution partners, or contract-value data, customer-acquisition strategy and revenue predictability cannot be assessed. Investment-relevant unknowns include ownership structure, key therapeutic categories, marketing-authorisation footprint across EU/EEA or other jurisdictions, and whether the company is primarily a developer (own dossiers) or a distributor/marketer of in-licensed generics.

Short descriptiontext

Verisfield is a Greek pharmaceutical company that develops and markets generic pharmaceutical products. Founded in 2000 and headquartered in Athens, it operates as a private, for-profit firm with 51–100 employees serving the generics segment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
generic pharmaceuticals, pharmaceutical development, pharmaceutical marketing, generic drug products, pharmaceutical distribution
Industry2 codes
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
Social media profiles1 record
Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Verisfield is a private pharmaceutical company headquartered in Athens, Greece, that specializes in the development and marketing of generic pharmaceutical products. The company focuses on bringing generic equivalents of established pharmaceutical formulations to market. With a workforce of 51-100 employees, it operates as a for-profit business entity serving the pharmaceutical sector.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeBroad incumbent
Description

European-focused generic and consumer healthcare company, now PE-owned. Comparable in EU generics focus and mid-sized European footprint, though at much larger scale; an active consolidator in the segment.

TypeDirect peer
Description

Greek pharmaceutical group with generics, OTC, and consumer healthcare products. Comparable in Greek home market presence, generics portfolio, and mid-cap size profile.

TypeBroad incumbent
Description

US-headquartered but with significant European generics operations and a portfolio-builder strategy. Comparable in generics focus and active M&A-driven expansion across European markets.

4Specifar Pharmaceuticals (Aenova)
TypeDirect peer
Description

Greek-based generic pharmaceutical company specializing in development and manufacturing of generics, now part of Aenova Group. Closely comparable generics developer-marketer with Greek footprint.

TypeDirect peer
Description

Greek pharmaceutical company marketing generic and OTC products domestically and in regional markets. Comparable in size, generics focus, and Greek/EU distribution orientation.

6Sandoz (Novartis)
TypeBroad incumbent
Description

Global leader in generics and biosimilars, spun off from Novartis. Comparable product category with strong European commercial presence; represents the upper bound of generic scale and pricing power.

TypeDirect peer
Description

Greek-based pharmaceutical company focused on branded generics and specialty products with in-house manufacturing. Directly comparable to Verisfield in terms of geography, generics focus, and mid-sized European footprint.

TypeBroad incumbent
Description

Slovenian-headquartered generic pharmaceutical manufacturer with strong Central/Eastern European presence. Comparable in generics-only model and European regional orientation.

TypeBroad incumbent
Description

World's largest generic pharmaceutical company with broad portfolio across all therapeutic areas. Comparable product category but vastly larger scale and global reach; sets the competitive benchmark for European generic pricing.

TypeDirect peer
Description

One of Greece's largest generic pharmaceutical manufacturers with strong development and export capabilities. Highly comparable in product category (sterile generics and injectables) and Greek home market positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verisfield

Generic Pharmaceuticalsverisfield.gr

Verisfield is a Greek pharmaceutical company that develops and markets generic pharmaceutical products. Founded in 2000 and headquartered in Athens, it operates as a private, for-profit firm with 51–100 employees serving the generics segment.

What Verisfield does

Verisfield is a Greek pharmaceutical company that specialises in the development and marketing of generic pharmaceutical products. Founded in 2000 and headquartered in Athína (Athens), the company operates as a for-profit private entity with a headcount of 51–100 employees. Its business model is anchored in the generics segment, where value is created by developing, registering, and commercialising off-patent pharmaceutical products for therapeutic substitution at lower price points than originator brands.

The input source material returned a loading/verification page rather than substantive company content, and most standard data fields — revenue, leadership, product list, partnerships, funding, technology stack, geographic footprint, certifications, and customer base — are not populated. As a result, the technical architecture, specific product portfolio, regulatory authorisations, distribution channels, and end-customer segments are not documented. Operating geography is limited to a single disclosed location (Athens), and the website domain (verisfield.gr) suggests a primary Greek market orientation, though export activity cannot be confirmed from the available data.

Revenue mechanics, pricing model, and go-to-market motion are not disclosed. In the absence of named customers, distribution partners, or contract-value data, customer-acquisition strategy and revenue predictability cannot be assessed. Investment-relevant unknowns include ownership structure, key therapeutic categories, marketing-authorisation footprint across EU/EEA or other jurisdictions, and whether the company is primarily a developer (own dossiers) or a distributor/marketer of in-licensed generics.

Verisfield firmographics

Firmographics
Name
Verisfield
Website
https://verisfield.gr
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Verisfield is a Greek pharmaceutical company that develops and markets generic pharmaceutical products. Founded in 2000 and headquartered in Athens, it operates as a private, for-profit firm with 51–100 employees serving the generics segment.
Ownership category
akta.pro rank

Verisfield industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical development
  • Pharmaceutical marketing
  • Generic drug products
  • Pharmaceutical distribution

Where Verisfield is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Markets served

Verisfield business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Verisfield product offering

Product offering

Core offering

Verisfield is a private pharmaceutical company headquartered in Athens, Greece, that specializes in the development and marketing of generic pharmaceutical products. The company focuses on bringing generic equivalents of established pharmaceutical formulations to market. With a workforce of 51-100 employees, it operates as a for-profit business entity serving the pharmaceutical sector.

Differentiator

Problem solved

Functional benefit

Companies that use Verisfield

Customer profile

Ideal customer profiles1 record

Verisfield technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Verisfield competitors and assessment

Company assessment

Broad incumbents

  • STADA Arzneimittel: European-focused generic and consumer healthcare company, now PE-owned. Comparable in EU generics focus and mid-sized European footprint, though at much larger scale; an active consolidator in the segment.
  • Alvogen: US-headquartered but with significant European generics operations and a portfolio-builder strategy. Comparable in generics focus and active M&A-driven expansion across European markets.
  • Sandoz (Novartis): Global leader in generics and biosimilars, spun off from Novartis. Comparable product category with strong European commercial presence; represents the upper bound of generic scale and pricing power.
  • KRKA: Slovenian-headquartered generic pharmaceutical manufacturer with strong Central/Eastern European presence. Comparable in generics-only model and European regional orientation.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical company with broad portfolio across all therapeutic areas. Comparable product category but vastly larger scale and global reach; sets the competitive benchmark for European generic pricing.

Direct peers

  • Lavipharm: Greek pharmaceutical group with generics, OTC, and consumer healthcare products. Comparable in Greek home market presence, generics portfolio, and mid-cap size profile.
  • Specifar Pharmaceuticals (Aenova): Greek-based generic pharmaceutical company specializing in development and manufacturing of generics, now part of Aenova Group. Closely comparable generics developer-marketer with Greek footprint.
  • Help Pharmaceuticals: Greek pharmaceutical company marketing generic and OTC products domestically and in regional markets. Comparable in size, generics focus, and Greek/EU distribution orientation.
  • ELPEN Pharmaceutical Co. Greek-based pharmaceutical company focused on branded generics and specialty products with in-house manufacturing. Directly comparable to Verisfield in terms of geography, generics focus, and mid-sized European footprint.
  • DEMO Pharmaceuticals: One of Greece's largest generic pharmaceutical manufacturers with strong development and export capabilities. Highly comparable in product category (sterile generics and injectables) and Greek home market positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks1 record

Key highlights1 record

Customer concentration

Verisfield social profiles

Digital presence

Verisfield financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verisfield leadership team

Management profile

Number of profiles

Verisfield funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verisfield M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verisfield

What does Verisfield do?

Verisfield is a private pharmaceutical company headquartered in Athens, Greece, that specializes in the development and marketing of generic pharmaceutical products. The company focuses on bringing generic equivalents of established pharmaceutical formulations to market. With a workforce of 51-100 employees, it operates as a for-profit business entity serving the pharmaceutical sector.

When was Verisfield founded?

Verisfield was founded in 2000. It employs 51 to 100 people.

Where is Verisfield based?

Verisfield is headquartered in Athens, Greece, in the Europe region.

Who are Verisfield's main competitors?

Broad incumbents on record are STADA Arzneimittel, Alvogen, Sandoz (Novartis), KRKA and Teva Pharmaceutical Industries. Direct peers are Lavipharm, Specifar Pharmaceuticals (Aenova), Help Pharmaceuticals, ELPEN Pharmaceutical Co. and DEMO Pharmaceuticals.

Does Verisfield have an API?

No public API is recorded for Verisfield.

What industry is Verisfield in?

Verisfield's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals